Alnylam Pharmaceuticals Company

Alnylam (Nasdaq: ALNY) is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeuticsrepresent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

Connections from

Industry: PharmTech
Headquarters: Zug

Visit Website
Register and Claim Ownership